This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Maintenance therapy in UC

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Ulcerative colitis:

  • in UC the objective of maintenance therapy should be to maintain steroid free remission (clinically and endoscopically defined) (1)
  • medications used for maintenance therapy include
    • aminosalicylate (5-ASA) – first line drugs used in patients responding to 5-ASA or steroids (oral or rectal)
    • thiopurines – used in patients who experience relapses or are intolerant to 5-ASA, patients who are steroid dependent or patients responding to ciclosporin for induction of remission
    • infliximab – used in patients responding to infliximab
    • probiotics (1)
  • good evidence in ulcerative colitis that aminosalicylates are effective in the prevention of relapses
  • also some evidence that the use of aminosalicylates may lead to a reduction in risk of colorectal cancer (1)

NICE suggest (2):

Pharmacological management - maintaining remission

Proctitis and proctosigmoiditis

  • to maintain remission after a mild-to-moderate inflammatory exacerbation of proctitis or proctosigmoiditis, consider the following options, taking into account the person's preferences:

    • a topical aminosalicylateU1 alone (daily or intermittent), OR

    • an oral aminosalicylateU2 plus a topical aminosalicylateU1 (daily or intermittent), OR ,

    • an oral aminosalicylateU2 alone, explaining that this may not be as effective as combined treatment or an intermittent topical aminosalicylate alone

Left-sided and extensive UC

  • to maintain remission in adults after a mild-to-moderate inflammatory exacerbation of left-sided or extensive UC:
    • a low maintenance dose of an oral aminosalicylate should be offered,
    • when deciding which oral aminosalicylate to use, take into account the person's preferences, side effects and cost

  • to maintain remission in children and young people after a mild-to-moderate inflammatory exacerbation of left-sided or extensive UC:
    • an oral aminosalicylate U2, U5 should be offered
    • when deciding which oral aminosalicylate to use, take into account the person's preferences (and those of their parents or carers as appropriate), side effects and cost.

All extents of disease

  • consider oral azathioprine U6 or oral mercaptopurine U6 to maintain remission:
    • after >=2 inflammatory exacerbations in 12 months that require treatment with systemic corticosteroids, OR
    • if remission is not maintained by aminosalicylates

  • to maintain remission after a single episode of acute severe UC:
    • consider oral azathioprineU6 or oral mercaptopurineU6
    • consider oral aminosalicylates if azathioprine and/or mercaptopurine are contraindicated or the person cannot tolerate them.

Dosing regimen for oral aminosalicylates

  • consider a once-daily dosing regimen for oral aminosalicylates U7 when used for maintaining remission
    • take into account the person' preferences, and explain that once-daily dosing can be more effective, but may result in more side effects.

Notes:

  • Unlicensed prescribing
    • U1 - some topical aminosalicylates are not licensed for this indication in children and young people.
    • U2 - some oral aminosalicylates are not licensed for this indication in children and young people.
    • U3 - beclometasone dipropionate only has a UK marketing authorisation 'as add-on therapy to 5-ASA containing drugs in patients who are non-responders to 5-ASA therapy in active phase'. Additionally, budesonide (oral or rectal) and prednisolone foam are not licensed in children.
    • U4 - ciclosporin is not licensed for this indication
    • U5 - dosing requirements for children should be calculated by body weight, as described in the BNF
    • U6 - although use is common in UK clinical practice, not all brands of azathioprine and mercaptopurine are licensed for this indication
    • U7 - at the time of publication, not all oral aminosalicylates are licensed for once-daily dosing. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.